First Citizens BancShares Inc vs Novo Nordisk A/S — how do they compare? First Citizens BancShares Inc trades at $2,249.28 (market cap $25.04B), while Novo Nordisk A/S trades at $45.76 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.3× First Citizens BancShares Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| FCNCA | NVO | |
|---|---|---|
Market Cap | $25.04B | $207.85B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $63.98 |
52-Week Low | $1.64K | $35.29 |
Dividend Yield | 0.37% | 3.81% |
Enterprise Value | — | $222.55B |
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,218.49, down 0.85% on the day, with strong technical indicators showing a bullish trend. The company demonstrates solid fundamentals with a P/E of 11.98, net income margin of 25.23%, and consistent earnings beats in recent quarters. Recent business developments include expansion of working capital finance services and strategic leadership appointments to drive growth across central U.S. markets.
FCNCA presents a mixed outlook with strong profitability metrics and positive earnings momentum offset by cautious analyst sentiment (81.82% hold rating). The stock trades below consensus price target of $2,310, offering potential upside, though risks include contracting net interest margins and elevated uninsured deposits at 38.3% of total deposits.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →